Hansa Medical granted patents in the United States and Europe for the medical use of IdeS
The granted IdeS patents, U.S. Patent 8,133,483 and European patent EP 1,901,773 , cover the use of IdeS in a method for the treatment or prevention of diseases mediated by IgG antibodies, including transplant rejection and autoimmune diseases.
IdeS is Hansa Medical’s most important biopharmaceutical development program. The IgG specific enzyme IdeS is being developed for use as a once-only treatment prior to kidney transplantation of sensitized transplantation patients. Sensitized transplantation patients have significant serum levels of donor specific antibodies, making it especially challenging to find a suitable organ donor for these patients. IdeS neutralizes IgG antibodies and has the potential to make sensitized patients transplantable, and thereby shorten the waiting time for these patients. The program is in late preclinical development and the results from toxicology and safety studies are currently being evaluated. Clinical phase I studies are scheduled for mid 2012.